Global Terbinafine Hydrochloride Drug Market Research Report 2021

Terbinafine, sold under the brand name Lamisil among others, an antifungal medication used to treat pityriasis versicolor, fungal nail infections, and ringworm including jock itch and athlete's foot. It is either taken by mouth or applied to the skin as a cream or ointment. The cream and ointment are not effective for nail infections.

The global Terbinafine Hydrochloride Drug market was valued at US$ XX million in 2020 and is expected to reach US$ XX million by the end of 2027, growing at a CAGR of XX% during 2021-2027.
This report focuses on Terbinafine Hydrochloride Drug volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Terbinafine Hydrochloride Drug market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.

Global Terbinafine Hydrochloride Drug Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type
Topical
Oral

Segment by Application
Fingernail Infection
Toenail Infection
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E

By Company
Novartis
GSK
TEVA
Dr. Reddy's Laboratories
CIPLA LTD
TARO
InvaGen Pharmaceuticals
Breckenridge Pharmaceutical
Harris Pharmaceutical
Glenmark
Orchid Healthcare
APOTEX
Jilin Wantong Group
Cussess
Hubei Hengan Fulin Pharm
Xiuzheng Pharmaceutical